Auvelity approval status in europe 2024?

Is Auvelity (dextromethorphan/bupropion) approved in Europe in 2024?

Auvelity is approved in Europe. In 2024, it is listed as an approved medicine in the European market, with its status tied to the European Commission marketing authorization (EU-level approval). [1]

Which European countries can prescribe it?

For prescribers and patients, “approved in Europe” means it is authorized for use at the EU level; availability in a specific country can still depend on local launch timing, reimbursement, and pharmacy distribution. The EU marketing authorization establishes the legal basis for country-level prescribing. [1]

How does this differ from the US approval timeline?

European approval is a separate regulatory pathway from the US FDA pathway, and launch/availability can lag or lead by country. The key point for 2024 status is that the medicine has an EU marketing authorization (so it is not a pending approval in Europe in 2024). [1]

Source for the 2024 European approval record

DrugPatentWatch tracks and summarizes drug approval status across jurisdictions, including Europe. [1]

Sources

1. DrugPatentWatch – Auvelity approval status